Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04729959 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 3 of 3 changed
See other at-risk trials from National Cancer Institute (NCI)

Record History

The 50 most recent of 168 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Completion pushed from Sep 4, 2026 to Aug 20, 2027
  2. Re-verified, no change to tracked fields
  3. Completion date: Sep 4, 2026 to Aug 20, 2027 Secondary endpoints: details revised at 3 of 5 entries · Study description revised · Site details revised at 10 of 110 sites Show 3 more changesShow less
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description revised
    • Site details revised at 10 of 110 sites
  4. Primary endpoint(s) modified Trial arms changed: 3 → 6 · Study sites revised (110)v166 Show 2 more changesShow less
    • Trial arms changed: 3 → 6
    • Study sites revised (110)

    See this version in full on ClinicalTrials.gov ↗

  5. Results first posted: Aug 7, 2026v165
Show 46 earlier versionsHide 46 earlier versions
  1. Enrollment target: 59 to 61 Secondary endpoints revised (5)v164 Show 1 more changeShow less
    • Secondary endpoints revised (5)

    See this version in full on ClinicalTrials.gov ↗

  2. Study description expanded, about 72 words Study arms: 3 to 6v163 Show 1 more changeShow less
    • Study arms: 3 to 6

    See this version in full on ClinicalTrials.gov ↗

  3. 6 versions Re-verified since Mar 24, 2026, no change to tracked fieldsv157-v162
  4. Study sites revised (110)v156 See this version in full on ClinicalTrials.gov ↗
  5. Re-verified, no change to tracked fieldsv155
  6. Study sites: 111 to 110v154
  7. Re-verified, no change to tracked fieldsv153
  8. Completion date: Jul 29, 2026 to Sep 4, 2026v152
  9. Study Status, Study Description, Arms and Interventionsv151
  10. Enrollment target: estimated 53 to confirmed 59 Primary completion date changed from estimate of Aug 14, 2025 to Jun 15, 2025 · Completion date: Aug 14, 2025 to Jul 29, 2026v150 Show 2 more changesShow less
    • Primary completion date changed from estimate of Aug 14, 2025 to Jun 15, 2025
    • Completion date: Aug 14, 2025 to Jul 29, 2026
  11. Study sites revised (111)v149 See this version in full on ClinicalTrials.gov ↗
  12. Study sites revised (111)v148 See this version in full on ClinicalTrials.gov ↗
  13. Re-verified, no change to tracked fieldsv147
  14. Study sites revised (111)v146 See this version in full on ClinicalTrials.gov ↗
  15. Re-verified, no change to tracked fieldsv145
  16. Primary and study completion dates: Jun 1, 2025 to Aug 14, 2025v144
  17. Trial status: Recruiting to Active, Not Recruiting Site details revised at 111 of 111 sitesv143 Show 1 more changeShow less
    • Site details revised at 111 of 111 sites
  18. Site details revised at 1 of 111 sitesv142
  19. Study sites: 110 to 111v141
  20. Study sites revised (110)v140 See this version in full on ClinicalTrials.gov ↗
  21. Site details revised at 1 of 110 sitesv139
  22. Re-verified, no change to tracked fieldsv138
  23. Study sites revised (110)v137 See this version in full on ClinicalTrials.gov ↗
  24. Site details revised at 1 of 110 sitesv136
  25. Site contacts updated at 4 of 110 sitesv135
  26. Study sites: 109 to 110v134
  27. Study sites: 108 to 109v133
  28. Study sites: 104 to 108v132
  29. Site details revised at 1 of 104 sitesv131
  30. Site details revised at 1 of 104 sitesv130
  31. Site contacts updated at 1 of 104 sitesv129
  32. Site details revised at 1 of 104 sitesv128
  33. Site details revised at 1 of 104 sitesv127
  34. Site details revised at 1 of 104 sitesv126
  35. Site details revised at 1 of 104 sitesv125
  36. Site details revised at 1 of 104 sitesv124
  37. Re-verified, no change to tracked fieldsv123
  38. Site details revised at 1 of 104 sitesv122
  39. Site details revised at 1 of 104 sitesv121
  40. Site details revised at 2 of 104 sitesv120
  41. Study Status, Contacts/Locationsv119
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent). Tocilizumab is a monoclonal antibody that binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body as well as certain types of cancer. This may help lower the body's immune response and reduce inflammation. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Fractionated stereotactic radiation therapy uses special equipment to precisely deliver multiple, smaller doses of radiation spread over several treatment sessions to the tumor. The goal of this study is to change a tumor that is unresponsive to cancer therapy into a more responsive one. Therapy with fractionated stereotactic radiotherapy in combination with tocilizumab may suppress the inhibitory effect of immune cells surrounding the tumor and consequently allow an immunotherapy treatment by atezolizumab to activate the immune response against the tumor. Combination therapy with tocilizumab, atezolizumab and fractionated stereotactic radiation therapy may shrink or stabilize the cancer better than radiation therapy alone in patients with recurrent glioblastoma.
Trial Details
NCT Number NCT04729959
Lead Sponsor National Cancer Institute (NCI)
Collaborators: NRG Oncology
Conditions Diffuse Astrocytoma, IDH-Wildtype, Recurrent Glioblastoma
Enrollment 61 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov